Phase 3 randomized study of Daratumumab plus lenalidomide and Dexamethasone (D-Rd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA)

Weisel, K (author)

Facon, T (author)

Kumar, S (author)

show more...

Plesner, T (author)

Orlowski, RZ (author)

Moreau, P (author)

Bahlis, N (author)

Basu, S (author)

Nahi, H (author)

Karolinska Institutet

Hulin, C (author)

Quach, H (author)

Goldschmidt, H (author)

O'Dwyer, M (author)

Perrot, A (author)

Venner, CP (author)

Mace, JR (author)

Ahmadi, T (author)

Chiu, C (author)

Wang, J (author)

van Rampelbergh, R (author)

Uhlar, CM (author)

Kobos, R (author)

Qi, M (author)

Usmani, SZ (author)

show less...

 (creator_code:org_t)

2019

2019

English.

In: ONCOLOGY RESEARCH AND TREATMENT. - 2296-5270. ; 42, s. 194-194

Related links:

http://kipublication...

• Conference paper (other academic/artistic)